Key Takeaways
- Vantage Biosciences has completed enrollment in the phase 2 SeeClear trial evaluating oral AOC3 inhibitor oruvestat for moderate-to-severe NPDR, with topline data expected in Q4 2027
- Oruvestat is being developed as a noninvasive, oral therapy intended to target inflammation and neurovascular dysfunction early in diabetic retinopathy
- The global, placebo-controlled study is being conducted at 26 sites across the United States, Australia, and Southeast Asia
Vantage Biosciences has completed patient enrollment in its phase 2 SeeClear (VX01-DR-201) clinical trial evaluating oruvestat (VX-01), an investigational oral therapy for non-proliferative diabetic retinopathy (NPDR).
The randomized, double-masked, placebo-controlled study has reached its recruitment target across participating sites in the United States, Australia, and Southeast Asia. With enrollment complete, all participants have entered the 52-week treatment and follow-up phase. The company expects topline results in the fourth quarter of 2027.
Oruvestat is an orally administered inhibitor of amine oxidase copper containing 3 (AOC3), an enzyme implicated in the inflammatory and neurovascular processes associated with diabetic retinopathy. By targeting upstream disease biology, the investigational therapy is intended to slow or halt disease progression and potentially improve retinopathy severity before patients require invasive treatment.
"Closing enrollment on plan across three global regions is a credit to our investigators, site teams and the patients who chose to participate in this exciting research," said Charmaine O'Neill, vice president of clinical operations at Vantage Biosciences. "Our focus now shifts to the quality of execution through the 52-week treatment period."
The SeeClear trial is enrolling patients with moderate-to-severe NPDR and is registered on ClinicalTrials.gov under identifier NCT06770933. Participants are randomized to receive either oruvestat or placebo for 52 weeks.
